PubMed Health⌕ Search

PubMed · 2493720

Transplantation in hyperimmunized patients.

Abstract

The accumulation of highly sensitized patients on waiting lists for renal transplantation is a universal problem. Because these patients have alloantibodies against many HLA alloantigens, it is difficult to find a cross-match-negative graft for them. As a result, their average waiting time is much longer than that of patients with fewer or no alloantibodies. Also, because the outcome of transplantation in highly immunized patients is generally less good, the result is a relatively great number of highly sensitized patients returned to the waiting list for retransplantation. In this paper we will deal with three topics: Why patients become highly sensitized, and what strategies are available to increase the chance of finding a donor for highly immunized patients, comprise two topics. The third is the description of a special strategy developed in our center to predict and select cross-match-negative donors for highly sensitized patients.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

F H Claas, J J van Rood. 1989. Transplantation in hyperimmunized patients.. https://pubmed.ncbi.nlm.nih.gov/2493720/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Soluble HLA revisited.

The goal of this editorial is to revisit soluble human leukocyte antigens (sHLA) and to highlight the findings reported by Albitar et al. in this issue on the relation between sHLA levels in Non-Hodgkin's Lymphoma (NHL) and Hodgkin's Disease (HD). We will review key aspects of sHLA including soluble HLA-G, which has received a lot of attention in recent publications. We will then address the role of sHLA in lymphoproliferative diseases and in solid organ tumors. Lastly, we will comment on the results of Albitar et al. and their relevance to clinical application in NHL.

HLA Antigens↗

Impact of KIR/HLA ligand combinations on immune responses in malignant melanoma.

Tumor growth and dissemination depend partly on the reactivity of natural killer (NK) cells and T cells expressing NK-associated receptors. Their effector functions are regulated by an array of activating and inhibitory cell surface receptors with MHC class I ligand specificity, such as the killer immunoglobulin-like receptors (KIRs). Given the extensive genomic diversity of KIRs and their HLA ligands, it is reasonable to speculate that HLA, KIR gene variations and specific KIR-ligand combinations will have an impact on disease susceptibility and/or progression. Here, we discuss how KIR genotypes and KIR/HLA immunogenetic profiles may be involved in tumorigenesis, especially in malignant melanoma (MM). A hypothetical model of the impact of KIR/ligand combinations on immune responses in MM is proposed.

HLA Antigens↗